Development of an immune-related prognostic index associated with osteosarcoma

References

• Zheng W, Huang Y, Chen H, et al. Nomogram application to predict overall and cancer-specific survival in osteosarcoma. Cancer Manag Res. 2018;10:5439–5450.
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125:229–234.
   PubMed Web of Science ®Google Scholar
• Kovac M, Blattmann C, Ribi S, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat. Commun. 2015;6:8940.
   PubMed Web of Science ®Google Scholar
• Dennis G Jr., Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:P3.
   PubMed Web of Science ®Google Scholar
• Kawano M, Tanaka K, Itonaga I, et al. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma. Oncol Rep. 2015;34:1995–2001.
   PubMed Web of Science ®Google Scholar
• Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020;21:541–550.
   PubMed Web of Science ®Google Scholar
• Peng YX, Yu B, Qin H, et al. EMT-related gene expression is positively correlated with immunity and may be derived from stromal cells in osteosarcoma. PeerJ. 2020;8:e8489.
   PubMed Web of Science ®Google Scholar
• Wu CC, Beird HC. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11:1008.
   PubMed Web of Science ®Google Scholar
• Belisario DC, Akman M, Godel M, et al. ABCA1/ABCB1 ratio determines chemo- and immune-sensitivity in human osteosarcoma. Cells. 2020;9.
   Web of Science ®Google Scholar
• Alves PM, de Arruda JAA, Arantes DAC, et al. Evaluation of tumor-infiltrating lymphocytes in osteosarcomas of the jaws: a multicenter study. Virchows Archiv. 2019;474:201–207. .
   PubMed Web of Science ®Google Scholar
• Zhang ML, Chen L, Li YJ, et al. PD‑L1/PD‑1 axis serves an important role in natural killer cell‑induced cytotoxicity in osteosarcoma. Oncol Rep. 2019;42:2049–2056.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
   PubMed Web of Science ®Google Scholar
• Liao Y, Chen L, Feng Y, et al. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget. 2017;8:30276–30287.
   PubMedGoogle Scholar
• Shen JK, Cote GM, Choy E, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2:690–698.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–287.
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–945.
   PubMed Web of Science ®Google Scholar
• Singh R, Mishra MK, Aggarwal H. Inflammation, immunity, and cancer. Mediators Inflamm. 2017;2017:6027305.
   PubMed Web of Science ®Google Scholar
• Fan TM, Roberts RD, Lizardo MM. Understanding and modeling metastasis biology to improve therapeutic strategies for combating osteosarcoma progression. Front Oncol. 2020;10:13.
   PubMed Web of Science ®Google Scholar
• Otoukesh B, Boddouhi B, Moghtadaei M, et al. Novel molecular insights and new therapeutic strategies in osteosarcoma. Cancer Cell Int. 2018;18:158.
   PubMed Web of Science ®Google Scholar
• Mangogna A, Cox MC, Ruco L, et al. Rituximab plus chemotherapy provides no clinical benefit in a peripheral T-Cell lymphoma not otherwise specified with aberrant expression of CD20 and CD79a: a case report and review of the literature. Diagnostics (Basel). 2020;10:341.
   Google Scholar
• Hof J, Visser L, Höppener DJ, et al. B cells as prognostic biomarker after surgery for colorectal liver metastases. Front Oncol. 2020;10:249.
   PubMed Web of Science ®Google Scholar
• Fujiyoshi S, Honda S, Minato M, et al. Hypermethylation of CSF3R is a novel cisplatin resistance marker and predictor of response to postoperative chemotherapy in hepatoblastoma. Hepatol Res. 2020;50:598–606.
   PubMed Web of Science ®Google Scholar
• Su L, Gao S. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations. Ann Hematol. 2019;98:1641–1646. .
   PubMed Web of Science ®Google Scholar
• Liu L, Wang T, Yang X, et al. MTNR1B loss promotes chordoma recurrence by abrogating melatonin-mediated β-catenin signaling repression. J Pineal Res. 2019;67:e12588.
   PubMed Web of Science ®Google Scholar
• Liu J, Clough SJ, Hutchinson AJ, et al. MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu Rev Pharmacol Toxicol. 2016;56:361–383.
   PubMed Web of Science ®Google Scholar
• Strazza M, Mor A. The complexity of targeting chemokines to promote a tumor immune response. Inflammation. 2020. DOI:10.1007/s10753-020-01235-8
   PubMed Web of Science ®Google Scholar
• Sautès-Fridman C, Cherfils-Vicini J, Damotte D, et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev. 2011;30:13–25.
   PubMed Web of Science ®Google Scholar
• Yu L, Zhong L, Xiong L, et al. Neutrophil elastase-mediated proteolysis of the tumor suppressor p200 CUX1 promotes cell proliferation and inhibits cell differentiation in APL. Life Sci. 2020;242:117229.
   PubMed Web of Science ®Google Scholar
• Al-Hakami A, Alqhatani SQ. Cytokine physiognomies of MSCs from varied sources confirm the regenerative commitment post-coculture with activated neutrophils. J Cell Physiol. 2020. DOI:10.1002/jcp.29713
   PubMed Web of Science ®Google Scholar
• Li Y, Hodge J, Liu Q, et al. TFEB is a master regulator of tumor-associated macrophages in breast cancer. J Immunother Cancer. 2020;8. DOI:10.1136/jitc-2020-000543.
   Web of Science ®Google Scholar
• Azambuja JH, Ludwig N. Arginase-1+ exosomes from reprogrammed macrophages promote glioblastoma progression. Int J Mol Sci. 2020;21. DOI:10.3390/ijms21113990
   Web of Science ®Google Scholar